215 related articles for article (PubMed ID: 37311690)
21. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
22. A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Grassl N; Poschke I; Lindner K; Bunse L; Mildenberger I; Boschert T; Jähne K; Green EW; Hülsmeyer I; Jünger S; Kessler T; Suwala AK; Eisele P; Breckwoldt MO; Vajkoczy P; Grauer OM; Herrlinger U; Tonn JC; Denk M; Sahm F; Bendszus M; von Deimling A; Winkler F; Wick W; Platten M; Sahm K
Nat Med; 2023 Oct; 29(10):2586-2592. PubMed ID: 37735561
[TBL] [Abstract][Full Text] [Related]
23. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
24. Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.
Zang D; Dong Z; Liu Y; Chen Q
BMC Neurol; 2024 Feb; 24(1):74. PubMed ID: 38383423
[TBL] [Abstract][Full Text] [Related]
25. Spinal intramedullary H3K27M mutant glioma with vertebral metastasis: a case report.
Handis C; Tanrıkulu B; Danyeli AE; Özek MM
Childs Nerv Syst; 2021 Dec; 37(12):3933-3937. PubMed ID: 33742289
[TBL] [Abstract][Full Text] [Related]
26. Prediction of H3K27M mutation status of diffuse midline gliomas using MRI features.
Chauhan RS; Kulanthaivelu K; Kathrani N; Kotwal A; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
J Neuroimaging; 2021 Nov; 31(6):1201-1210. PubMed ID: 34189806
[TBL] [Abstract][Full Text] [Related]
27. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
Agarwal P; Aiyer HM
Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
[TBL] [Abstract][Full Text] [Related]
28. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Cantor E; Wierzbicki K; Tarapore RS; Ravi K; Thomas C; Cartaxo R; Nand Yadav V; Ravindran R; Bruzek AK; Wadden J; John V; May Babila C; Cummings JR; Rahman Kawakibi A; Ji S; Ramos J; Paul A; Walling D; Leonard M; Robertson P; Franson A; Mody R; Garton HJL; Venneti S; Odia Y; Kline C; Vitanza NA; Khatua S; Mueller S; Allen JE; Gardner SL; Koschmann C
Neuro Oncol; 2022 Aug; 24(8):1366-1374. PubMed ID: 35137228
[TBL] [Abstract][Full Text] [Related]
29. Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study.
Wang Y; Feng LL; Ji PG; Liu JH; Guo SC; Zhai YL; Sankey EW; Wang Y; Xue YR; Wang N; Lou M; Xu M; Chao M; Gao GD; Qu Y; Gong L; Wang L
Front Oncol; 2020; 10():602553. PubMed ID: 33659209
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathological characteristics of H3K27-altered diffuse midline glioma and evaluation of NTRK as its therapeutic target].
Duan ZJ; Feng J; Yao K; Hu ZJ; Ma Z; Xiang L; Zhang XF; Qi XL
Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1115-1122. PubMed ID: 36323540
[No Abstract] [Full Text] [Related]
31. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.
Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V
Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217
[TBL] [Abstract][Full Text] [Related]
32. Pediatric midline H3K27M-mutant tumor with disseminated leptomeningeal disease and glioneuronal features: case report and literature review.
Navarro RE; Golub D; Hill T; McQuinn MW; William C; Zagzag D; Hidalgo ET
Childs Nerv Syst; 2021 Jul; 37(7):2347-2356. PubMed ID: 32989496
[TBL] [Abstract][Full Text] [Related]
33. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
[TBL] [Abstract][Full Text] [Related]
34. H3K27M mutant glioma: Disease definition and biological underpinnings.
Saratsis AM; Knowles T; Petrovic A; Nazarian J
Neuro Oncol; 2024 May; 26(Supplement_2):S92-S100. PubMed ID: 37818718
[TBL] [Abstract][Full Text] [Related]
35. Diffuse midline glioma H3K27M mutation in adult: A case report.
Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
[TBL] [Abstract][Full Text] [Related]
36. Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
Sharma M; Barravecchia I; Magnuson B; Ferris SF; Apfelbaum A; Mbah NE; Cruz J; Krishnamoorthy V; Teis R; Kauss M; Koschmann C; Lyssiotis CA; Ljungman M; Galban S
Neoplasia; 2023 Oct; 44():100931. PubMed ID: 37647805
[TBL] [Abstract][Full Text] [Related]
37. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
[TBL] [Abstract][Full Text] [Related]
38. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.
Grimaldi S; Harlay V; Appay R; Bequet C; Petrirena G; Campello C; Barrié M; Autran D; Boissonneau S; Graillon T; Figarella-Branger D; Nanni I; Chinot O; Tabouret E
J Neurooncol; 2022 Feb; 156(3):615-623. PubMed ID: 34994963
[TBL] [Abstract][Full Text] [Related]
39. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
Zhao H; Fang X; Xue B
Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
[TBL] [Abstract][Full Text] [Related]
40. Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas.
Mosaab A; El-Ayadi M; Khorshed EN; Amer N; Refaat A; El-Beltagy M; Hassan Z; Soror SH; Zaghloul MS; El-Naggar S
Sci Rep; 2020 May; 10(1):8368. PubMed ID: 32433577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
